NeurogesX reports positive Phase III data

NeurogesX is touting positive data from the second late-stage study of NGX-4010, a dermal patch therapy for patients with postherpetic neuralgia. The study hit its primary endpoint with a 32 percent reduction in pain from baseline from a single 60-minute application of NGX-4010 as compared to a 24 percent reduction in pain in the control group. The study also hit all of its secondary endpoints.

- see the release on the trial results

Related Article:
NeurogesX blueprints IPO plans. Report

Suggested Articles

Bristol Myers Squibb is teaming up with Repare Therapeutics to find new synthetic lethality targets in a deal that could be worth billions.

Biotech Orpheris has been given the FDA go-ahead for a phase 2 aimed at calming the cytokine storm sometimes caused by COVID-19.

PureTech plans to start a trial in the emerging population of patients who survive COVID-19 only to suffer lasting damage in the third quarter.